Gambaran Umum
Aptose Biosciences Inc., based in Canada, operates within the biotechnology sector, focusing primarily on the development of novel therapies that target the underlying mechanisms of cancer. This clinical-stage company concentrates on developing personalized oncology drugs that halt aberrant cell growth and proliferation essential to hematologic cancers and solid tumors. Key projects include HM43239, an oral myeloid kinase inhibitor currently in clinical development for acute myeloid leukemia (AML), and APTO-253, which is the company's leading candidate targeting the c-Myc oncogene in hematologic cancers and solid tumors. These projects reflect Aptose Biosciences' strategic focus on addressing significant unmet medical needs in the oncology field.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Aptose Biosciences Inc. per 2025 Jun 30 adalah -21.53 MM.
- Nilai net income untuk Aptose Biosciences Inc. per 2025 Jun 30 adalah -21.12 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -21.53 | -21.12 | |
2025-03-31 | -21.96 | -21.33 | |
2024-12-31 | -26.26 | -25.43 | |
2024-09-30 | -36.20 | -35.80 | |
2024-06-30 | -40.91 | -40.29 | |
2024-03-31 | -48.02 | -47.17 | |
2023-12-31 | -52.36 | -51.21 | |
2023-09-30 | -50.63 | -49.25 | |
2023-06-30 | -48.98 | -47.58 | |
2023-03-31 | -45.20 | -44.02 | |
2022-12-31 | -42.60 | -41.82 | |
2022-09-30 | -56.55 | -56.15 | |
2022-06-30 | -57.88 | -57.70 | |
2022-03-31 | -60.70 | -60.61 | |
2021-12-31 | -65.45 | -65.35 | |
2021-09-30 | -55.86 | -55.74 | |
2021-06-30 | -57.79 | -57.66 | |
2021-03-31 | -60.19 | -59.94 | |
2020-12-31 | -55.77 | -55.24 | |
2020-09-30 | -48.89 | -48.23 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -13.04.
- laba per saham yang terdilusi untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -13.04.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -13.04 | -13.04 |
2025-03-31 | -19.03 | -19.03 |
2024-12-31 | -36.38 | |
2024-09-30 | -76.48 | -76.48 |
2024-06-30 | -108.74 | -108.74 |
2024-03-31 | -166.58 | -166.58 |
2023-12-31 | -227.43 | |
2023-09-30 | -233.36 | -233.49 |
2023-06-30 | -230.76 | -230.76 |
2023-03-31 | -214.49 | -216.51 |
2022-12-31 | -203.98 | |
2022-09-30 | -275.90 | -274.79 |
2022-06-30 | -286.14 | -286.31 |
2022-03-31 | -303.30 | -299.63 |
2021-12-31 | -330.12 | -328.50 |
2021-09-30 | -282.09 | -281.46 |
2021-06-30 | -294.28 | -292.47 |
2021-03-31 | -317.32 | -317.32 |
2020-12-31 | -303.74 | |
2020-09-30 | -292.20 | -292.20 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Aptose Biosciences Inc. per 2025 Jun 30 adalah -27.17 MM.
- Nilai cash from investing activities untuk Aptose Biosciences Inc. per 2025 Jun 30 adalah 0.00 MM.
- Nilai kas dari aktivitas pendanaan untuk Aptose Biosciences Inc. per 2025 Jun 30 adalah 20.14 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -27.17 | 0.00 | 20.14 |
2025-03-31 | -27.01 | 2.01 | 22.40 |
2024-12-31 | -35.98 | 0.02 | 33.41 |
2024-09-30 | -37.18 | 1.96 | 27.46 |
2024-06-30 | -37.34 | 14.91 | 22.36 |
2024-03-31 | -45.05 | 10.93 | 18.71 |
2023-12-31 | -44.59 | 9.96 | 6.91 |
2023-09-30 | -43.98 | 25.59 | 6.11 |
2023-06-30 | -40.42 | 7.56 | 1.23 |
2023-03-31 | -33.98 | 19.60 | 0.15 |
2022-12-31 | -32.32 | 30.07 | 0.12 |
2022-09-30 | -39.72 | -7.52 | 0.13 |
2022-06-30 | -40.80 | -2.62 | 0.11 |
2022-03-31 | -42.57 | -7.69 | 0.17 |
2021-12-31 | -43.30 | -35.21 | 0.23 |
2021-09-30 | -37.61 | 12.76 | 0.20 |
2021-06-30 | -37.84 | 8.56 | 58.48 |
2021-03-31 | -36.16 | 5.04 | 58.45 |
2020-12-31 | -33.89 | 12.63 | 58.81 |
2020-09-30 | -29.77 | -23.61 | 132.41 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 |
Efektivitas Manajemen
- roa untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -1.95.
- roic untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -12.17.
- croic untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -1.48.
- ocroic untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -15.41.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -1.95 | -12.17 | -1.48 | -15.41 | |
2025-03-31 | -1.99 | -185.62 | -16.02 | -4.89 | -23.43 |
2024-12-31 | -2.76 | -4.19 | -0.91 | -4.35 | |
2024-09-30 | -1.93 | -4.60 | |||
2024-06-30 | -1.20 | -1.81 | -44.67 | -14.60 | -42.66 |
2024-03-31 | -1.00 | -1.09 | -5.82 | -3.15 | -5.07 |
2023-12-31 | -0.86 | -1.05 | -5.54 | -1.38 | -4.95 |
2023-09-30 | -0.73 | -0.86 | -3.17 | -2.11 | -2.70 |
2023-06-30 | -0.68 | -0.79 | -3.17 | -2.11 | -2.70 |
2023-03-31 | -0.61 | -0.67 | -1.62 | -0.52 | -1.25 |
2022-12-31 | -0.58 | -0.57 | -1.19 | -1.00 | -0.84 |
2022-09-30 | -0.58 | -0.57 | -1.19 | -1.00 | -0.84 |
2022-06-30 | -0.54 | -0.59 | -1.03 | -0.77 | -0.73 |
2022-03-31 | -0.53 | -0.55 | -0.92 | -0.76 | -0.65 |
2021-12-31 | -0.52 | -0.55 | -0.87 | -1.05 | -0.58 |
2021-09-30 | -0.41 | -0.43 | -0.56 | -0.25 | -0.38 |
2021-06-30 | -0.68 | -0.73 | -0.58 | 0.30 | -0.38 |
2021-03-31 | -0.65 | -0.69 | -0.54 | 0.25 | -0.33 |
2020-12-31 | -0.55 | -0.59 | -0.46 | 0.31 | -0.28 |
2020-09-30 | -1.49 | -1.76 | -0.37 | 0.61 | -0.23 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 882361 |
Grupong Pang-industriya
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech) |